Clinical Outcomes and Self-Reported Symptoms in Patients With Acromegaly: An 8-Year Follow-Up of a Lanreotide Study
| Autor: | Shafaq Khairi, Babak Torabi Sagvand, Anne Klibanski, Karen J. Pulaski-Liebert, Lisa B. Nachtigall, Nicholas A. Tritos |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adenoma
Adult Male medicine.medical_specialty Pediatrics Endocrinology Diabetes and Metabolism MEDLINE Antineoplastic Agents 030209 endocrinology & metabolism Lanreotide Peptides Cyclic 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Open label study Quality of life Acromegaly Humans Medicine In patient Insulin-Like Growth Factor I General hospital Aged business.industry Patient Preference General Medicine Middle Aged medicine.disease Magnetic Resonance Imaging Clinical trial chemistry Delayed-Action Preparations Quality of Life Physical therapy Female Self Report Growth Hormone-Secreting Pituitary Adenoma Somatostatin business 030217 neurology & neurosurgery Follow-Up Studies |
| Zdroj: | Endocrine Practice. 23:56-65 |
| ISSN: | 1530-891X |
| DOI: | 10.4158/ep161439.or |
| Popis: | The aim of this study was to evaluate the proportion of patients with acromegaly who remained on long-term lanreotide depot after completion of an open-label multicenter phase III clinical trial (SALSA: A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel), compare baseline and long-term follow-up symptoms scores, and correlate scores with individual longitudinal clinical outcomes.Records of all subjects previously enrolled at the Massachusetts General Hospital site of SALSA were reviewed. Those who remained on lanreotide were interviewed and asked to complete a questionnaire that they had filled out in SALSA in 2007 regarding their current symptomatology and injection side effects, as well as to complete the Acromegaly Quality of Life Questionnaire. Furthermore, clinical, biochemical, and radiographic data related to acromegaly and its comorbidities were tracked throughout follow-up.Six out of 7 patients chose to remain on lanreotide, and 5 of them continued lanreotide depot through last follow-up, for up to 8 years or in 1 case until death. In all cases, lanreotide remained well tolerated, and insulin-like growth factor-1 levels and pituitary imaging remained well controlled on stable doses. While comorbidities persisted or developed, the self-reported symptom score after up to 8 years of therapy showed a significant decrease in frequency or resolution in symptoms that were reported at baseline.This study shows a significant decrease in frequency or resolution in self-reported symptoms in well-controlled patients receiving long-term lanreotide therapy.AcroQoL = Acromegaly Quality of Life Questionnaire GH = growth hormone GI = gastrointestinal IGF-1 = insulin-like growth factor-1 SALSA = A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|